dalbavancin
Dalvance
Pharmaceutical company: Allergan
NEW INDICATION & DOSAGE
Acute bacterial skin and skin-structure infections caused by susceptible strains of gram-positive microorganisms (Staphylococcus aureus [including MRSA], Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus dysgalactiae, Streptococcus anginosus group [S. anginosus,S. intermedius, S. constellatus], Enterococcus faecalis (vancomycin-susceptible strains)
Children age 6 to less than 18: 18 mg/kg IV infusion as a single dose, up to a maximum of 1,500 mg.
Children from birth to less than age 6: 22.5 mg/kg IV infusion as a single dose, up to a maximum of 1,500 mg.
Adjust-a-dose: Dose adjustment for children with creatinine clearance less than 30 mL/minute has not been established.
Released: October 2021
Nursing Drug Handbook
© 2021 Wolters Kluwer
empagliflozin
Jardiance
Pharmaceutical company: Boehringer Ingelheim and Eli Lilly
NEW INDICATION & DOSAGE
To reduce the risk of CV death or hospitalization for heart failure in patients with heart failure and reduced ejection fraction
Adults: 10 mg PO daily in the morning.
CONTRAINDICATIONS & CAUTIONS
- Not recommended for glycemic control in patients with eGFR less than 30 mL/min/1.73 m2.
- Dosing recommendations have not been determined for patients with type 2 diabetes and established CV disease with eGFR less than 30 mL/min/1.73 m2, or who have heart failure with reduced ejection fraction with eGFR less than 20 mL/min/1.73 m2.
Released: October 2021
Nursing Drug Handbook
© 2021 Wolters Kluwer
immune globulin IV (human)
Octagam
Pharmaceutical company: Octapharma
NEW INDICATION & DOSAGE
Dermatomyositis (Octagam 10%)
Adults: 2 g/kg divided in equal doses given over 2 to 5 consecutive days every 4 weeks. Initial infusion rate is 0.01 mL/kg/min (1 mg/kg/min) for the first 30 minutes. If tolerated, the rate may be gradually increased to 0.02 mL/kg/min (2 mg/kg/min) and, if tolerated, may gradually increase to a maximum of 0.04 mL/kg/min (4 mg/kg/min).
Alert: Patients with dermatomyositis are at increased risk for thromboembolic events; do not exceed infusion rate of 0.04 mL/kg/min.
Released: October 2021
Nursing Drug Handbook
© 2021 Wolters Kluwer
ivosidenib
Tibsovo
Pharmaceutical company: Servier Pharmaceuticals
NEW INDICATION & DOSAGE
Locally advanced or metastatic cholangiocarcinoma with IDH1 mutation as detected by an FDA-approved test in patients who have been previously treated
Adults: 500 mg PO daily until disease progression or unacceptable toxicity occurs.
Released: October 2021
Nursing Drug Handbook
© 2021 Wolters Kluwer
lenvatinib
Lenvima
Pharmaceutical company: Eisai, Inc.
NEW INDICATION & DOSAGE
Advanced endometrial carcinoma that is not microsatellite instability-high or mismatch repair deficient in patients who have disease progression after systemic therapy in any setting and who are not candidates for curative surgery or radiation, in combination with pembrolizumab
Adults: 20 mg PO once daily until disease progression or unacceptable toxicity occurs. Give with pembrolizumab according to the manufacturer's prescribing information.
Released: October 2021
Nursing Drug Handbook
© 2021 Wolters Kluwer
mepolizumab
Nucala
Pharmaceutical company: GlaxoSmithKline
NEW INDICATION & DOSAGE
Maintenance treatment of chronic rhinosinusitis with nasal polyps in patients with inadequate response to nasal corticosteroids
Adults: 100 mg subcut once every 4 weeks into upper arm, thigh, or abdomen.
Released: October 2021
Nursing Drug Handbook
© 2021 Wolters Kluwer
nivolumab
Opdivo
Pharmaceutical company: Bristol Myers Squibb
NEW INDICATION & DOSAGE
Adjuvant treatment of urothelial carcinoma in patients who are at high risk for recurrence after undergoing radical resection
Adults: 240-mg IV infusion every 2 weeks, or 480-mg IV infusion every 4 weeks, until disease recurrence or unacceptable toxicity occurs, or up to 1 year of treatment.
Released: October 2021
Nursing Drug Handbook
© 2021 Wolters Kluwer
pembrolizumab
Keytruda
Pharmaceutical company: Merck Sharp & Dohme
NEW INDICATION & DOSAGE
Advanced endometrial carcinoma that is not microsatellite instability-high or mismatch repair deficient in patients who have disease progression after systemic therapy in any setting and who are not candidates for curative surgery or radiation, in combination with lenvatinib
Adults: 200-mg IV infusion every 3 weeks or 400-mg IV infusion every 6 weeks until disease progression or unacceptable toxicity occurs, or up to 24 months in patients without disease progression. Give with lenvatinib according to the manufacturer's prescribing information.
High-risk, early-stage triple-negative breast cancer (TNBC) in combination with chemotherapy as neoadjuvant treatment, and then continued as a single-agent adjuvant treatment after surgery
Adults: Neoadjuvant treatment in combination with chemotherapy for 24 weeks (8 doses of 200-mg IV infusion every 3 weeks, or 4 doses of 400-mg IV infusion every 6 weeks), followed by adjuvant treatment as a single agent for up to 27 weeks (9 doses of 200-mg IV infusion every 3 weeks, or 5 doses of 400-mg IV infusion every 6 weeks) or until disease progression or unacceptable toxicity occurs. Give prior to chemotherapy when given on the same day.
Locally recurrent unresectable or metastatic TNBC in patients whose tumors express PD-L1 as determined by an FDA-approved test, in combination with chemotherapy
Adults: 200 mg every 3 weeks or 400 mg every 6 weeks, until disease progression or unacceptable toxicity occurs or up to 24 months in patients without disease progression. Give prior to chemotherapy when given on the same day.
Released: October 2021
Nursing Drug Handbook
© 2021 Wolters Kluwer
rivaroxaban
Xarelto
Pharmaceutical company: Janssen
NEW INDICATION & DOSAGE
To reduce the risk of major thrombotic vascular events in patients with peripheral artery disease (PAD), including patients after recent lower extremity revascularization due to symptomatic PAD, once hemostasis is established
Adults: 2.5 mg PO b.i.d., in combination with aspirin (75 to 100 mg) once daily.
Released: October 2021
Nursing Drug Handbook
© 2021 Wolters Kluwer